Last Update Time:
21-Mar-2025 16:00:00
ISIN:
INE600L01024
Sector:
Healthcare
Symbol:
LALPATHLAB
Dr. Lal Path Labs Ltd.
₹2,517.25
₹-1.00
(-0.04%)
▼
Prev. Close
₹2,518.25
Open
₹2,506.80
Close
₹2,533.85
Range
₹2,391.39 - ₹2,643.11
High
₹2,557.35
Low
₹2,498.00
Ind. Close
₹0.00
VWAP
₹2,525.16
The current stock price of Dr. Lal Path Labs Ltd. is ₹2,517.25, with a target price range between ₹2,391.39 and ₹2,643.11. The stock has experienced a price change of ₹-1.00 (-0.04%), reflecting recent market volatility.
Today's opening price was ₹2,506.80, while the previous close stood at ₹2,518.25.
The market trend suggests a potential downtrend, with investors exercising caution due to recent declines. Analysts recommend closely monitoring support levels.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Dr. Lal Path Labs Ltd. Price Chart
Dr. Lal Path Labs Ltd. Pre Open Market Overview: 21-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 2506.8
- Previous Close Price: 2518.25
- Change: -11.45%
- Total Traded Volume: 152
- Total Buy Quantity: 1,116
- Total Sell Quantity: 1,428
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 2,505.05 | 2.00 | 0.00 |
| 2,506.05 | 2.00 | 0.00 |
| 2,506.20 | 100.00 | 0.00 |
| 2,506.75 | 11.00 | 0.00 |
| 2,506.80 | 18.00 | 0.00 |
| 2,519.95 | 0.00 | 1.00 |
| 2,522.45 | 0.00 | 1.00 |
| 2,524.95 | 0.00 | 1.00 |
| 2,527.45 | 0.00 | 1.00 |
| 2,529.95 | 0.00 | 1.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 1116
Total Sell Quantity: 1428
Shareholding Patterns of Dr. Lal Path Labs Ltd.
Key Trade Statistics of Dr. Lal Path Labs Ltd.
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 1.58 |
| Traded Value (₹ Cr.) | 39.81 |
| Total Market Cap (₹ Cr.) | 21,042.13 |
| Free Float Market Cap (₹ Cr.) | 9,394.09 |
| Impact cost | 0.04 |
| Quantity Traded | 157,672.00 |
| Deliverable Quantity | 98,095.00 |
| % of Quantity to Traded | 62.21 |
| Security VaR | 11.55 |
| Index VaR | N/A |
| VaR Margin | 11.55 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 15.05 |
| Face Value | 10 |
Key Price Statistics of Dr. Lal Path Labs Ltd.
The 52-week high for Dr. Lal Path Labs Ltd. was ₹3,653.95, recorded on 10-Oct-2024. On the other hand, the 52-week low stands at ₹2,014.90, with the lowest value recorded on 20-Mar-2024.
The upper band for trading is ₹3,021.90, and the lower band is ₹2,014.60. The price band is 20%.
The stock's daily volatility stands at 1.82, while the annualized volatility is 34.77. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (10-Oct-2024) | 3,653.95 |
| 52 Week Low (20-Mar-2024) | 2,014.90 |
| Upper Band | 3,021.90 |
| Lower Band | 2,014.60 |
| Price Band (%) | 20 |
| Daily Volatility | 1.82 |
| Annualised Volatility | 34.77 |
| Tick Size | 0.05 |
Key Securities Statistics of Dr. Lal Path Labs Ltd.
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 23-Dec-2015 |
| Adjusted P/E | 49.82 |
| Symbol P/E | 49.82 |
| Index | NIFTY 500 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Healthcare Services |
| Basic Industry | Healthcare Service Provider |
Security Status of Dr. Lal Path Labs Ltd.
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Dr. Lal Path Labs Ltd.
| Subject | Date |
|---|---|
| Analysts/Institutional Investor Meet/Con. Call Updates | 20-Mar-2025 |
| Update-Acquisition/Scheme/Sale/Disposal-XBRL | 19-Mar-2025 |
| General Updates | 18-Mar-2025 |
| Credit Rating- Others | 14-Mar-2025 |
| Shareholders meeting | 10-Mar-2025 |
| Alteration Of Capital and Fund Raising-XBRL | 18-Feb-2025 |
| ESOP/ESOS/ESPS | 18-Feb-2025 |
| Copy of Newspaper Publication | 08-Feb-2025 |
Corporate Actions of Dr. Lal Path Labs Ltd.
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 10 | Interim Dividend - Rs 6 Per Share | 05-Feb-2025 |
| 10 | Interim Dividend - Rs 6 Per Share | 05-Nov-2024 |
| 10 | Interim Dividend - Rs 6 Per Share | 20-Aug-2024 |
| 10 | Dividend - Rs 6 Per Share | 10-Jun-2024 |
| 10 | Interim Dividend - Rs 12 Per Share | 13-Feb-2024 |
| 10 | Dividend - Rs 6 Per Share | 11-Aug-2023 |
| 10 | Interim Dividend - Rs 6 Per Share | 11-Aug-2023 |
| 10 | Interim Dividend - Rs 6 Per Share | 05-Aug-2022 |
| 10 | Annual General Meeting/Dividend - Rs 6 Per Share | 22-Jun-2022 |
| 10 | Interim Dividend - Rs 6 Per Share | 18-Aug-2021 |
| 10 | Annual General Meeting/Dividend - Rs 8 Per Share | 20-Jul-2021 |
| 10 | Interim Dividend - Rs 6.00 Per Share | 09-Feb-2021 |
| 10 | Interim Dividend - Rs 6 Per Share | 18-Nov-2020 |
| 10 | Interim Dividend - Rs 6 Per Share | 05-Mar-2020 |
| 10 | Interim Dividend - Rs 6 Per Share | 20-Nov-2019 |
| 10 | Annual General Meeting/ Dividend - Rs 3.5 Per Share | 02-Aug-2019 |
| 10 | Interim Dividend - Rs 2.50 Per Share | 19-Nov-2018 |
| 10 | Annual General Meeting / Dividend- Rs 3 Per Share | 03-Aug-2018 |
| 10 | Interim Dividend Rs 1.50 Per Share | 20-Nov-2017 |
| 10 | Annual General Meetin/Dividend - Rs 1.70 Per Share | 12-Jul-2017 |
Board Meetings of Dr. Lal Path Labs Ltd.
Financial Results of Dr. Lal Path Labs Ltd.
Company Directory of Dr. Lal Path Labs Ltd.
| Web Address | Office | Address | City |
|---|---|---|---|
| www.lalpathlabs.com | Head Office/ Corporate Office | 12th Floor, Tower B, SAS Tower, Sector 38, Medicity, | GURGAON |
| www.lalpathlabs.com | Registered Office | Block E, Sector 18 Rohini, New Delhi -110085. | NEW DELHI |
| www.lalpathlabs.com | Transfer Agent | C 101, 247 Park, L.B.S Marg Vikhroli West | MUMBAI |
Insider Trading of Dr. Lal Path Labs Ltd.
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Om Prakash Manchanda | 51170371 | Sell |
| 7(2) | Dr. Lal PathLabs Employees Welfare Trust | 5380 | Sell |
| 7(2) | Rahul Sharma | 3131100 | Sell |
| 7(2) | Prashant Kishore | 11240 | Buy |
| 7(2) | PUNIT SHARMA | 1026248 | Buy |
| 7(2) | Shankha Banerjee | 10000 | Buy |
| 7(2) | Dr. Lal PathLabs Employees Welfare Trust | 1600973 | Sell |
| 7(2) | Om Prakash Manchanda | 29181785 | Sell |
| 7(2) | Ved Prakash Goel | 16250 | Buy |
| 7(2) | Dr. Lal PathLabs Employees Welfare Trust | 249324 | Sell |
| 7(2) | Nimish Jindal | 5750 | Buy |
| 7(2) | Om Prakash Manchanda | 42853145 | Sell |
| 7(2) | Dr. Lal PathLabs Employees Welfare Trust | 476478 | Sell |
| 7(2) | Rahul Sharma | 1245200 | Buy |
| 7(2) | Shankha Banerjee | 10000 | Buy |
| 7(2) | Om Prakash Manchanda | 28219200 | Sell |
| 7(2) | Dr. Lal PathLabs Employees Welfare Trust | 26460 | Sell |
| 7(2) | Nimish Jindal | 6750 | Buy |
| 7(2) | Rahul Sharma | 14800961 | Sell |
| 7(2) | Saloni Rakesh Khera | 4000 | Buy |
Annual Reports of Dr. Lal Path Labs Ltd.
Investor Complaints of Dr. Lal Path Labs Ltd.
Event Calendar of Dr. Lal Path Labs Ltd.
| Purpose | Details |
|---|---|
| Results | to inter-alia consider and approve the un-audited financial results of the Company for the quarter and nine-months ended December 31, 2015. |
| Results/Dividend | To inter-alia consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended March 31, 2016 and to consider recommending dividend, if any, on Equity Shares of the Company for the year ended March 31, 2016. |
| Results | To inter-alia consider and approve the unaudited financial results of the Company for the Quarter ended June 30, 2016. |
| Results | Inter-alia consider and approve the unaudited financial results of the Company for the quarter & half year ended September 30, 2016. |
| Results/Dividend | To inter-alia consider and approve the un-audited financial results of the Company for the Quarter ended December 31, 2016 and to consider the proposal of payment on interim dividend, if any, for the financial Year 2016-17. Further, the Trading Window, as per the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's code for Prevention of Insider Trading, will be closed from January 01, 2017 till February 04, 2017 for the purpose of announcement / declaration of such results by the Company. |
| Results/Dividend | To inter-alia consider and approve the Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2017 and to consider recommending Final Dividend, if any, on Equity Shares of the Company for the Financial Year ended March 31, 2017. Further the Trading Window, as per the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company s code for Prevention of Insider Trading, will be closed from April 01, 2017 till May 14, 2017 for the purpose of announcement / declaration of such results by the Company. |
| Results | To inter-alia consider and approve the unaudited Financial Results of the Company for the Quarter ended June 30, 2017. |
| Results/Dividend | To inter-alia consider and approve the un-audited financial results of the Company for the Quarter & Half Year ended September 30, 2017 and to consider the proposal of payment of interim dividend, if any, for the Financial Year 2017-18. |
| Results | To inter-alia consider and approve the un-audited Financial Results of the Company for the Quarter ended December 31, 2017.ￂﾠ |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2018 and dividend |
| Financial Results | To consider and approve the Unaudited financial results for the period ended Jun 30, 2018. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2018 and dividend |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2019 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2019 and to consider the proposalof declaration of interim dividend for the Financial Year 2019-20. |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2019 |
| Dividend | This is to inform you that a meeting of the Board of Directors is scheduled to be held on Tuesday, February 25, 2020 to inter-alia consider the proposal of declaration of 2nd interim dividend for theFinancial Year 2019-20. |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2020 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2020 and interim dividend, if any for the financial year 2020-21 |
| Financial Results/Dividend | To consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2020 and consider proposal of declaration of 2nd interim dividend, if any for the financial year 2020-21 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2021 and dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2021 and dividend |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Financial results | Dr. Lal Path Labs Ltd. has informed the Exchange about the Board Meeting to be held on 08-Nov-2022 to inter-alia consider and approve the Un-Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Half Year ended September 30, 2022. |
| Financial Results | To inter-alia consider and approve the un-audited financial results (Standalone & Consolidated) for the quarter and nine months ended December 31, 2022. |
| Financial Results/Dividend/Other business matters | To consider and approve the audited financial results (Standalone and Consolidated) for the period ended March 31, 2023, Final dividend, if any and other business matters |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results (Standalone and Consolidated) for the quarter ended June 30, 2023, interim dividend, if any and other business matters |
| Financial Results/Other business matters | To consider and approve the Unaudited financial results for the Quarter and Half Year ended September 30, 2023 and other business matters |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended December 31, 2023, dividend and other business matters |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2024, recommendation of final dividend, if any and other business matters |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2024, dividend and other business matters |
| Financial Results/Dividend/Other business matters | To consider and approve the un-audited financial results (Standalone and Consolidated) for the period ended September 30, 2024, dividend, if any and other business matters |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended December 31, 2024, dividend, if any and other business matters |
Share Transfers of Dr. Lal Path Labs Ltd.
Voting Results of Dr. Lal Path Labs Ltd.
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 09-MAR-2025 | Postal Ballot | Payment of Commission to Non-Executive Directors including Independent Directors |
| 09-MAR-2025 | Postal Ballot | Payment of Commission to Non-Executive Directors including Independent Directors |
| 29-JUN-2024 | AGM | To receive, consider and adopt the audited standalone financial statements of the Company for the financial year ended March 31, 2024 together with the reports of the Directors￢ﾀﾙ and Auditors￢ﾀﾙ thereon and the audited consolidated financial statements of the Company for the financial year ended March 31, 2024 together with report of Auditors' thereon. |
| 29-JUN-2024 | AGM | Ratification of Remuneration payable to Cost Auditors for the Financial Year 2024-25 |
| 29-JUN-2024 | AGM | Payment of remuneration to Mr. Rahul Sharma (DIN: 00956625), Non-Executive Director, in the event of exercise of ESOPs in excess of 50% of total remuneration payable to all Non-Executive Directorsn |
| 29-JUN-2024 | AGM | Re-appointment of Dr. Vandana Lal (DIN: 00472955) as Whole-Time Director of the Company |
| 29-JUN-2024 | AGM | To appoint a Director in place of Dr. Om Prakash Manchanda (DIN: 02099404), who retires by rotation and being eligible, offers himself for re-appointment. |
| 29-JUN-2024 | AGM | To declare final dividend of Rs. 6/- per fully paid-up equity share having face value of Rs. 10/- each for the financial year ended March 31, 2024 |
| 12-SEP-2023 | AGM | To receive, consider and adopt the audited standalone financial statements of the Company for the financial year ended March 31, 2023 together with the reports of the Directors￢ﾀﾙ and Auditors￢ﾀﾙ thereon and the audited consolidated financial statements of the Company for the financial year ended March 31, 2023 together with report of Auditors' thereon |
| 12-SEP-2023 | AGM | Ratification of Remuneration payable to Cost Auditors for the Financial Year 2023-24 |
| 12-SEP-2023 | AGM | Payment of remuneration to Directors in excess of 11% of Net Profits of the Company, in the event of exercise of ESOPs |
| 12-SEP-2023 | AGM | Payment of remuneration to Mr. Rahul Sharma (DIN: 00956625), Non-Executive Director, in the event of exercise of ESOPs in excess of 50% of total remuneration payable to all Non-Executive Directors |
| 12-SEP-2023 | AGM | Payment of remuneration in excess of 1% of Net Profits of the Company to Mr. Rahul Sharma (DIN: 00956625), Non-Executive Director, in the event of exercise of ESOPs |
| 12-SEP-2023 | AGM | Payment of remuneration in excess of 5% of Net Profits of the Company to Dr. Om Prakash Manchanda (DIN: 02099404), Managing Director, in the event of exercise of ESOPs |
| 12-SEP-2023 | AGM | Payment of Commission to Non-Executive Directors including Independent Directors |
| 12-SEP-2023 | AGM | Appointment of Mr. Rajit Mehta (DIN: 01604819) as an Independent Director of the Company |
| 12-SEP-2023 | AGM | Appointment of Mr. Gurinder Singh Kalra (DIN: 10197218) as an Independent Director of the Company |
| 12-SEP-2023 | AGM | To appoint a Director in place of Mr. Rahul Sharma (DIN: 00956625), who retires by rotation and being eligible, offers himself for re-appointment |
| 12-SEP-2023 | AGM | To declare final dividend of Rs. 6/- per fully paid equity share having face value of Rs. 10/- each for the Financial Year ended March 31, 2023 |
| 10-MAR-2023 | Postal Ballot | Appointment of Mr. Arun Duggal (DIN: 00024262) as an Independent Director of the Company |
FAQs on Dr. Lal Path Labs Ltd.
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.